Engineering the Next Generation of CAR T Therapy:
Dual target strategy; in vivo innovation
Pipeline
Tempest is a clinical-stage CAR-T company building the future of in vivo CAR-T therapy with broad potential benefit for patients with autoimmune diseases or cancer
News
July 15,
2026
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
June 4,
2026
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
May 29,
2026
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds